Brokers Set Expectations for Envoy Medical Q4 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Analysts at Brookline Capital Management decreased their Q4 2024 earnings estimates for shares of Envoy Medical in a research note issued to investors on Tuesday, November 19th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings of ($0.36) per share for the quarter, down from their prior estimate of ($0.29). Brookline Capital Management currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.07) per share. Brookline Capital Management also issued estimates for Envoy Medical’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.39) EPS.

Separately, Ascendiant Capital Markets increased their price target on Envoy Medical from $8.50 to $8.75 and gave the stock a “buy” rating in a report on Tuesday, September 3rd.

Envoy Medical Price Performance

Envoy Medical stock opened at $2.18 on Friday. Envoy Medical has a 1-year low of $1.01 and a 1-year high of $11.46. The company’s 50-day moving average is $2.67 and its 200 day moving average is $2.64.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Envoy Medical stock. Virtu Financial LLC purchased a new position in shares of Envoy Medical, Inc. (NASDAQ:COCH) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,045 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Envoy Medical at the end of the most recent quarter. Institutional investors and hedge funds own 8.59% of the company’s stock.

Envoy Medical Company Profile

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.